Ovarian Cancer: Closing Gaps and Advancing Care with RWD

Key Takeaways

• 21,000 U.S. women diagnosed with ovarian cancer in 2026.
• Deaths exceed 12,000 annually, despite 45% mortality decline since 1976.
• Only 4% of global R&D funding targets women’s cancers.
• 1,300‑1,500 gynecologic oncologists serve the U.S., creating access gaps.
• Real‑world data enables AI‑curated, diverse patient insights for trials.

Pulse Analysis

Ovarian cancer remains a silent epidemic in the United States, with roughly 21,000 new diagnoses slated for 2026 and over 12,000 deaths each year. The high mortality rate reflects systemic challenges: inadequate screening tools, pronounced racial disparities—Black women are diagnosed at later stages more often than White women—and a critical shortage of specialized gynecologic oncologists, especially in rural communities. Compounding these issues, women’s cancers receive merely 4% of global research and development dollars, limiting the pipeline of innovative therapies.

Real‑world data (RWD) is reshaping how clinicians and researchers understand ovarian cancer. Unlike traditional trial cohorts, RWD aggregates de‑identified patient information from electronic health records, claims, and disease registries, capturing the full spectrum of age, comorbidities, and treatment settings. AI‑driven curation extracts unstructured notes, ensuring high completeness for variables such as platinum‑resistance status, molecular profiling, and sequencing of therapies. This granular, longitudinal view reveals patterns of care that were previously invisible, allowing stakeholders to identify where gaps exist and which interventions deliver real‑world benefit.

The strategic value of RWD extends to drug development and trial design. By supplying external control arms and enabling adaptive enrollment, sponsors can accelerate study timelines while maintaining statistical rigor. Moreover, AI‑enhanced patient matching improves representation of historically under‑served groups, fostering equitable trial participation. As payers, providers, and regulators increasingly accept RWD as evidence, the oncology ecosystem moves closer to precision care that reflects the lived experience of all patients, not just idealized trial populations.